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Renal transplantation has had a significant impact on many patients with end-
stage renal disease. Unfortunately, there exists a large subgroup of dialysis pa-
tients who for immunological reasons cannot be transplanted (1). These patients 
have become sensitized to most or all HLA antigens from previous transplants, 
blood transfusions, or multiple pregnancies. They react strongly to all kidneys 
that become available and can spend years on transplant waiting lists. The ex-
ample of the waiting list at the University of Pittsburgh illustrates the problem 
(Table 1). Over one third of the patients on the list have a panel reactive antibody 
(PRA) level of greater than 80%, and over half have a PRA greater than 40%. 
Furthermore, when these patients are finally transplanted, their graft survival rate 
is inferior to that of low PRA patients (2) (Fig. O. Thus, the problem of the 
highly sensitized patient represents a significant impediment to progress in renal 
transplantation. 
The present approach to these patients involves waiting for a kidney with a 
negative crossmatch. Aggressive immunosuppression with cyclosporine, aza-
thioprine, and prednisone and usually with an antilymphocyte preparation can 
improve results to a 1 year graft survival rate of 75% (2) (Fig. 2). Unfortunately, 
relatively few patients can be treated in this manner. Only 15% of the patients 
that are transplanted at the authors' center have a PRA greater than 40%, and 
this figure is a result of an allocation policy designed to give priority to sensitized 
patients (3) (Table 2). 
A more effective technique of transplanting the sensitized patient must involve 
some mechanism of lowering the antibody level and maintaining it at a low level. 
In this regard, there are a few potentially useful techniques. One is thoracic duct 
drainage (TDD), which has had a long history in renal transplantation and which 
may have new applications because of recent technical developments. Another 
is plasmapheresis, which has been somewhat controversial. Finally, there is Staph 
A immunodepletion, which is currently in an early stage of development but 
which may become an important tool in the near future. This paper discusses 
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TABLE 1. University of Pittsburgh kidney transplantation waiting list, April 1989 
Panel reactive antibody level <40 40-80 >80 
Patients (number) 47 (48%) 15 (16%) 35 (36%) 
the development of and the experience with these three techniques and their ap-
plication to renal transplantation in sensitized patients. 
Thoracic Duct Drainage 
Experimental studies in the early 1960's demonstrated that chronic TOO led 
to a diminution of the primary antibody response in rats (4). In a rat skin graft 
model, pretreatment with TOO was associated with prolongation of graft sur-
vival; an interaction with an anti-lymphocyte preparation was also noted (5,6) 
(Table 3). A similar effect was seen in a canine renal allograft model (7). 
The first clinical use of TOO as pretreatment for renal transplantation was 
reported in 1964 by Franksson, who performed a successful living-related donor 
kidney transplant from father to son after 3 to 4 days of preoperative TDO (8). 
Subsequent work by Franksson et al. in Sweden has included over 50 patients 
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FIG. 1. Kidney transplantation: actuarial graft survival for high and low panel reactive antibody (PRA) 
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FIG. 2. Kidney transplantation: actuarial graft survival for high and low panel reactive antibody (PRA) 
patients with 3-drug and 2-drug immunosuppression. 
(9,10). Most of the patients had TDD started during the first week after trans-
plantation. Just under half of the patients also underwent thymectomy; some 
patients received anti-lymphocyte globulin as well. The results in living donor 
transplants showed no advantage, with excellent graft survival both in patients 
who had or did not have TOO (Table 4). However, in cadaver transplantation, 
1 year graft survival was significantly improved in patients who were treated 
with TOO. The length of time of TOO also seemed to be important. Graft sur-
vival was significantly better in patients who had 30 days or more of TOO com-
TABLE 2. Equitable allocation of organs-recipient selection factors 
Point system 
Waiting time 
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TABLE 4. One year actuarial graft survival 
TDD + (%) TDD - (%) 
Living-related donor 84 84 
Cadaver 72 47 
p < 0.05 
Reproduced, with permission, from Franksson C, Lungre G, Magnusson G, Ringden O. Drainage 
of thoracic duct lymph in renal transplant patients. Transplantation 1976;21:133-40. 
pared to those patients with less than 30 days of treatment (Table 5). The effects 
of TDD on the immune system included a significant depletion of lymphocytes 
from both lymph nodes and the peripheral blood although the latter effect was 
only noted after 2 to 3 weeks. Furthermore, serum immunoglobulin levels were 
seen to fall as well. Delayed hypersensitivity, as determined by the PPD skin 
test, also disappeared. 
The group at the Peter Bent Brigham Hospital in Boston accumulated expe-
TABLE 5. Actuarial graft survival 
1 year (%) 2 years (%) 
TDD 2: 30 days 85 85 
TDD :5 30 days 63 50 
p < 0.01 
Reproduced, with permission, from Franksson C. Lungre G, Magnusson G, Ringden O. Drainage 
of thoracic duct lymph in renal transplant patients. Transplantation 1976;21: 133-40. 
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rience with 22 cases of successful TDD in living-related donor transplants (11-
13). Patients were treated with TDD before transplantation for an average of 16 
days in the successfully treated group. The investigators found improved long-
term patient and graft survival in the treated group (Table 6). 
In Texas, the group at Galveston treated 14 patients with TDD prior to ca-
daveric renal transplantation (14). They also found lymphocyte depletion in lymph 
nodes as well as in the spleen and the intestine. Delayed hypersensitivity was 
also diminished although changes in the serum immunoglobulin levels were not 
apparent. These patients were not treated with additional immunosuppression 
initially; 8 patients had good long-term graft survival. 
The group at Vanderbilt University in Tennessee used TDD for 3 to 4 weeks 
as a pretreatment for cadaver renal transplantation (15,16). When a battery of 
immunological tests including skin testing, mixed lymphocyte culture, cell-mediated 
lympholysis assays, absolute lymphocyte counts, and T-cell rosetting demon-
strated a diminution of the immune response, the patients were transplanted with 
no attempt at HLA matching. Thoracic duct drainage led to significant improve-
ment in 1 year graft survival although there was no difference in patient survival 
(Table 7). 
In Denver, TDD before or after cadaver renal transplantation was performed 
in 83 patients between April 1978 and December 1979 (17-22). The initial re-
ports were enthusiastic. Problems of prolonged fistula patency and infections 
TABLE 6. Survival rates following living-related renal donor transplants 
Patient (%) Graft (%) 
TDD 73 73 
Attempted TDD 50 50 
NoTDD 42 27 
Reproduced, with permission, from Tilney NL, Atkinson Je, Murray JE. The immunosuppressive 
effect of thoracic duct drainage in human kidney transplantation. Ann Intern Med 1970;72:59-64. 
TABLE 7. One-year actuarial survival after cadaveric renal transplantation 
Patient (%) Graft (%) 
TDD + 83 76 
TDD - 88 48 
Reproduced, with permission, from Johnson HK, Niblack GD, Tallent MB, Richie RE. Immuno-
logic preparation for cadaver renal transplant by thoracic duct drainage. Transplant Proc 1977;9: 1499-
1503. 
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related to TDD were not major issues. Most of the patients were transplanted 
before the cyclosporine era, and excellent results were noted. Particular emphasis 
was given to prolonged pretreatment because these patients had the greatest ben-
efit. The investigators' final paper, in which 1 year or more follow-up was avail-
able on all 83 patients, represents a good summary of the results. The best out-
come was in patients who had 4 or more weeks of pretreatment with TDD: the 
1 year graft survival rate was 73%. Patients with less than 4 weeks' pretreatment 
had a I-year graft survival rate of 67% although that figure included 2 patients 
who were expected to lose their grafts, and the expectation was of an approxi-
mate graft survival rate of 50%. This latter figure was not substantially different 
from that of patients who had TDD started at the time of transplantation or those 
who did not undergo TDD at all (Fig. 3). 
Other early reports from around the world showed less impressive results (23-
26). With the exception of the experience in Nagoya, Japan, where excellent 
results have been obtained in living-related transplants (27-30) (Table 8), TDD 
has been largely abandoned throughout the world. There are several reasons for 
this. First, the TDD technique is not simple. Technical complications precluded 
its use in 20 to 50% of the cases even in experienced centers (10,12). Prolonged 
expensive hospitalization was required, infectious problems and even deaths oc-
curred. Thus, TDD was difficult, complicated, and expensive. Second, in spite 
of the good immunosuppressive effect of TDD, follow-up with the best immu-
nosuppressive protocols of that era, namely azathioprine, prednisone, and anti-
lymphocyte globulin, was insufficient to prevent late graft loss (22). Finally, the 
advent of cyclosporine, changing as it did the entire fabric of transplantation, 
rendered TDD superfluous. With the early results of 80 to 90% 1 year graft 
survival rates in the pioneering studies of cyclosporine in renal transplantation 
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FIG. 3. Effect of thoracic duct drainage (TOO) on graft survival in primary cadaveric kidney trans-
plantation, (Reprinted, with permission, from Surgery. Gynecology & Obstetrics 1981;153:377-82). 
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TABLE 8. One-year survival rates after living-related donor renal transplantation 
Patient (%J Graft (%J 
TOO + cyclosporine 87 87 
TOO + azathioprine 98 95 
Reproduced, with pennission, from Ohshima S, Ono Y, Kinukawa T, Matsuura 0, Takeuchi N, 
Hattori R. The long-tenn results of thoracic duct drainage in living related kidney transplantation. Trans-
plant Proc 1989;21:1972-3. 
(31) and the improved results in extrarenal transplantation (32), TOO was no 
longer needed for routine immunosuppression. 
The question remains whether there is a subset of patients in the cyclosporine 
era that would benefit from TOO. The most popular immunosuppressive pro-
tocols utilize triple drug or sequential 4 drug regimens and are associated with 
88% 1 year graft survival in first transplants. However, the group of sensitized 
patients remains more problematic. In this regard, the ability of TOO to deplete 
serum immunoglobulin may be important. Prolonged pretreatment with TOO might 
reduce the anti-HLA antibody levels to the point that sensitized patients would 
be able to undergo transplantation. The recent development of a new filter that 
can be adapted to TOO and utilized in a closed system may well simplify the 
procedure. At present, an experimental trial of this filter in the laboratory is being 
planned. If successful, a clinical trial in sensitized patients will be considered. 
Plasmapheresis 
Plasma exchange has been used in two different contexts in renal transplan-
tation. It has been used to remove anti-HLA antibodies as a pretreatment for 
transplantation, and it has also been utilized to treat humoral or antibody-mediated 
rejection. 
The pretreatment model has combined antibody reduction by plasmapheresis 
with immunosuppression to prevent antibody resynthesis. A specific anti-B cell 
agent, cyclophosphamide, was used in combination with azathioprine and pred-
nisolone. This work was done by Taube and his colleagues in London (33,34). 
They reported on 5 highly sensitized patients who were successfully transplanted. 
At least I of the patients was treated postoperatively with plasma exchange to 
combat a humoral rejection. There was 1 episode of severe sepsis leading to 
death in this group; this fact may have had some role in the abandonment of the 
trial. However, the technique did seem to be effective. 
In contrast, the use of plasma exchange to treat rejection has been less suc-
cessful. Although some writers have reported successful reversal of rejection 
(35-37), many have seen no benefit whatsoever and have pronounced it to be 
useless or worse (38). One of the first reports, by Cardella and his group in 
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Toronto, describes successful reversal of rejection in 5 of 7 episodes with suc-
cessful engraftment in 3 of 5 patients (35) (Table 9). Another study, by Naik 
et al. in England (36), describes favorable responses in 4 of 5 cases of rejection 
with 2 patients having good long-term graft survival. 
A controlled trial of plasmapheresis as a treatment for rejection, comparing 
plasmapheresis and steroids with steroids alone, showed that there was no benefit 
to plasma exchange (38) (Table 10). It should be noted that the steroid-only 
group received an average of 900 mg more intravenous steroid than the 
plasmapheresis-steroid group (2.1 vs. 1.2 g). Another study from Australia looked 
at 7 cases of rejection treated with plasmapheresis, with no patients having long-
term graft survival (39). Thus, at best, plasmapheresis has been associated with 
improved graft survival in a minority of cases; at worst, it has demonstrated no 
benefits. 
The disadvantages of plasmapheresis also include its expense and the need for 
transfusion with fresh frozen plasma. These issues, combined with the ques-
tionable benefits, have led to the near abandonment of plasma exchange in renal 
transplantation. However, there is some very preliminary evidence that there is 
a role for plasma exchange in the management of liver transplant patients in the 
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early postoperative period. This work, which is still in the early stages of eval-
uation in Pittsburgh, has used plasmapheresis to treat patients with early non-
functioning grafts (40). It is unclear whether the benefit is in supporting patients 
with livers that have suffered severe but reversible ischemic damage, or whether 
there is a component of humoral rejection that is being treated. What is clear is 
that there are several patients in whom at the very least the need for urgent 
retransplantation has been avoided by the use of plasma exchange. 
Staph A Immunodepletion 
A relatively new development that deals directly with the antibody problem 
utilizes the ability of the Staphylococcus aureus protein A to bind the Fc receptor 
of IgG (41). Although this observation is not new, it has recently become pos-
sible to attach protein A to a cyanogenbromide-activated sepharose and to man-
ufacture a column of bound protein A (Immunosorba-Excorim, DuPont). A com-
puter controlled device, the Citem-lO, which can control the flow of plasma and 
other solutions across the Staph A column, has been developed. A source of 
plasma from a standard plasmapheresis unit is linked in series with the Citem-
10, which contains two Staph A columns in parallel. As plasma passes over 1 
column, the IgG is adsorbed. Low pH citrate is used to elute the adsorbed an-
tibody as plasma is passed over the other Staph A column. Cycles of adsorption 
and elution are alternated every 10 min. The immunodepleted plasma is returned 
with the plasmapheresed red blood cells to the patient; because only the antibody 
is removed, transfusion of blood products is not necessary. It is possible to de-
plete serum IgG levels by 75 to 90% with a single treatment of 2 to 3 plasma 
volumes (42). Thus, Staph A immunodepletion can be used to reduce the level 
of anti-HLA antibodies in sensitized dialysis patients. 
While potentially exciting, the development of this new technology is not by 
itself the entire solution. Overnight rebound of IgG levels occurs initially, pre-
sumably secondary to reequilibration from the interstitium (42). Furthermore, as 
the antibody levels fall, the immune system compensates by resynthesizing IgG. 
Thus, Staph A immunodepletion must be combined with effective immuno-
suppression to maintain a low antibody titer. The most common regimen has 
utilized cyclophosphamide and steroids. 
In Europe, about 30 dialysis patients have been treated with Staph A immu-
no depletion (43). Five patients have withdrawn from the study, but only 1 was 
for a treatment-related problem, namely a reaction to citrate. Seventeen patients 
underwent transplantation; in 14 cases the pre-immunodepletion serum cross-
match was positive. Ten of these 14 transplants were successful. 
Taube et al. recently published their experience with their first 10 patients 
treated with immunodepletion (44,45). One patient withdrew because of an un-
related cause, a myocardial infarction, 1 month after treatment. Seven patients 
received transplants, and no kidneys were lost to hyperacute rejection although 
1 graft was lost to chronic rejection at 1 year and 1 graft never functioned. 
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In the United States, a multicenter trial of Staph A immunodepletion is being 
conducted at several university medical centers; currently, no patients have 
undergone transplantation. While the outcome is still unknown, the development 
of this new technology promises to be interesting and may have important im-
plications for the large number of sensitized patients on transplant waiting lists. 
Conclusion 
This paper has focused on solutions to the problem of renal transplantation in 
highly sensitized patients. The history of TDO has been presented, and its po-
tential application in this patient population has been described. The use of plasma 
exchange has been discussed, mainly to emphasize its lack of utility in renal 
transplantation although its application in certain cases of liver transplantation 
may prove to be lifesaving. Finally, the new technology of Staph A immunode-
pletion and its clinical application, which is still developmental, has been pre-
sented. What is clear is that a solution to the problem of the sensitized patient 
will require the ability to deal with the high levels of preformed antibodies. One 
or more of the techniques described here may well be used to solve this difficult 
clinical and immunological problem. 
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